<DOC>
	<DOCNO>NCT00136175</DOCNO>
	<brief_summary>This trial evaluate efficacy safety combination chemotherapy ( paclitaxel , carboplatin , gemcitabine ) prior surgery treatment patient locally advance transitional cell cancer bladder .</brief_summary>
	<brief_title>Paclitaxel , Carboplatin Gemcitabine Treatment Patients With Advanced Transitional Cell Cancer Bladder</brief_title>
	<detailed_description>This Phase II trial neoadjuvant chemotherapy paclitaxel , carboplatin gemcitabine treatment locally advance transitional cell carcinoma bladder . Patients stratify base extent disease . Patients T3 , N0 disease receive 3 cycle chemotherapy proceed cystectomy . Patients T4 disease patient N1-3 disease receive 3 cycle therapy follow assessment response . Patients evidence response receive additional three cycle therapy reassessment resectability cycle # 6 . Correlative Studies : Tumor specimen obtain initial biopsy assay expression p53 , Rb p21 .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Patients must histologically prove locally advanced ( T34 , N0 Tany , N13 ) urothelial carcinoma bladder . Patients local disease unilateral bilateral hydronephrosis eligible include T3 arm study . Tumor specimen must available assay molecular marker . ECOG ( Eastern Cooperative Oncology Group ) performance status 0 2 ( measure general well 0 asymptomatic 5 death ) Life expectancy 12 week Adequate bone marrow , renal hepatic function Patients may prior systemic intraarterial chemotherapy prior radiotherapy ( Patients may receive intravesicular chemotherapy ) . Evidence distant metastasis Unresolved bacterial infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Neoadjuvant chemotherapy</keyword>
</DOC>